Eckhart Weidmann
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 21
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 38
- Oncology top 1%
- Hematology top 1%
- Acute Myeloid Leukemia Research 13
- Immunology top 2%
- Immunotherapy and Immune Responses 17
- Immune Cell Function and Interaction 16
-
- Cell death mechanisms and regulation 15
- Renal and related cancers 11
-
- Acute Lymphoblastic Leukemia research 10
- Co-authors
- Lothar BergmannDieter HoelzerUlrich MaurerParis S. MitrouD. HoelzerJürgen BriegerMathias RummelT. Karakas
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Eckhart Weidmann
110 papers receiving 4.9k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Genetics 1.3k
- Pathology and Forensic Medicine 2.1k
- Oncology 2.0k
- Hematology 770
- Immunology 1.3k
Countries citing papers authored by Eckhart Weidmann
This map shows the geographic impact of Eckhart Weidmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eckhart Weidmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eckhart Weidmann more than expected).
Fields of papers citing papers by Eckhart Weidmann
This network shows the impact of papers produced by Eckhart Weidmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eckhart Weidmann. The network helps show where Eckhart Weidmann may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Eckhart Weidmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2015 | 64 | |
| 2 | 2014 | 12 | |
| 3 | 2014 | 44 | |
| 4 | Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialbreakdown → | 2013 | 962 |
| 5 | 2011 | 65 | |
| 6 | 2005 | 4 | |
| 7 | 2004 | 3 | |
| 8 | 2004 | 7 | |
| 9 | 2004 | 16 | |
| 10 | 2004 | 1 | |
| 11 | 2003 | 32 | |
| 12 | 2002 | 2 | |
| 13 | 2002 | 72 | |
| 14 | Cytotoxic hepatosplenic gammadelta T-cell lymphoma following acute myeloid leukemia bearing two distinct gamma chains of the T-cell receptor. Biologic and clinical features. | 2000 | 13 |
| 15 | 2000 | 18 | |
| 16 | 2000 | 2 | |
| 17 | 1999 | 22 | |
| 18 | 1995 | 24 | |
| 19 | 1995 | 73 | |
| 20 | 1990 | 18 |
About Eckhart Weidmann
Eckhart Weidmann is a scholar working on Pathology and Forensic Medicine, Genetics and Hematology, having authored 111 papers that have together received 5.0k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (38 papers), Chronic Lymphocytic Leukemia Research (21 papers), Immunotherapy and Immune Responses (17 papers), Immune Cell Function and Interaction (16 papers), Cell death mechanisms and regulation (15 papers), Acute Myeloid Leukemia Research (13 papers), Renal and related cancers (11 papers) and Acute Lymphoblastic Leukemia research (10 papers). The work is most often cited by research in Genetics (1.3k citations), Pathology and Forensic Medicine (2.1k citations) and Oncology (2.0k citations). Eckhart Weidmann has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Lothar Bergmann, Dieter Hoelzer, Ulrich Maurer, Paris S. Mitrou, D. Hoelzer, Jürgen Brieger, Mathias Rummel, T. Karakas, Wolfram Brugger and Ulrich Kaiser. Their work appears in journals such as Blood, Annals of Oncology, Leukemia Research, International Journal of Cancer and Annals of Hematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.